Tag: $AstraZeneca

AstraZeneca (AZN.L), on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the U.S., where it has invested $50 billion to expand amid tariff threats from Washington.

AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs.

Shares of AstraZeneca (ST:AZN) and GlaxoSmithKline (LON:GSK) fell on Wednesday after U.S. President Donald Trump said tariffs on imported drugs could be imposed “very soon.”

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.

UK drugmaker AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter of 2024.

AstraZeneca turned down an offer of nearly £80mn in UK state support when it abruptly cancelled plans for a £450mn vaccine manufacturing site near Liverpool, according to people briefed on the matter.

AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023.

Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year’s annual ‘Choose France’ business summit.

AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a “surplus of available updated vaccines” since the pandemic.

AstraZeneca sees its revenue and core earnings per share growing by double-digit percentages in 2024, the pharmaceuticals major said as it reported fourth-quarter core earnings per share below expectations on higher costs, sending the stock lower.

Icosavax stock soared 47% in Tuesday premarket trading after the Seattle-based vaccine developer reached a deal to be acquired by pharmaceutical giant AstraZeneca.

American depositary receipts of AstraZeneca were falling Monday after the drugmaker reported disappointing results from a Phase 3 trial of a lung- cancer drug.

AstraZeneca (AZN.L) said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.